About Us


Who We Are

CellAegis Devices Inc (CDI) is a Toronto-based designer and manufacturer of safe, non-invasive and cost effective, cardio protective medical devices. CellAegis is building on market acceptance of remote ischemic conditioning through continued support of clinical research projects and development of the market world-wide.

CellAegis Devices has developed and commercialized the non-invasive system, the autoRIC® System, which automates delivery of Remote Ischemic Conditioning (RIC) therapy. The autoRIC® is adjunct to standard of care, has the CE Mark and Health Canada Approval. CellAegis Devices is currently commercializing in Europe and Canada, and conducting registration trials in the USA.

Rocky Ganske

CEO


Mr. Ganske joined CellAegis in December 2010 as the CEO after having participated on the CellAegis Board of Directors for a year. Mr. Ganske has over 30 years of both public and private company experience in the medical devices, diagnostics and life science fields, and has a broad background in management, operations, science and regulatory; blended with the disciplines of corporate processes, and successful entrepreneurial business ventures. Mr. Ganske has personally led multiple business and IP transactions with both Fortune 100 and Fortune 500 companies.

Prior to CDI, Mr. Ganske served as CEO of Axela, a university diagnostics startup focused on proteomic analysis. Mr. Ganske transitioned Axela to a full operating company, installing Axela’s platform technology in premier institutes in the US, EU and Asia Pacific. Mr. Ganske was instrumental in negotiating and closing significant patent in-licensing transaction with Fortune 100 companies for over 150 patents and applications and oversaw Axela’s acquisition of Xceed Molecular, a genomics diagnostic company.

Mr. Ganske held the position of Chief Operating Officer at Third Wave Technologies (TWTI) in Madison, WI. During his eight year tenure at TWTI, Mr. Ganske was imperative in setting the operational vision and tactical implementation that grew TWTI from a company with great technology to a fully operational company with over $40M of revenue. Third Wave debuted on Nasdaq in February 2001 in an $83 Million IPO, and was bought by Hologic for over $300M.

Prior to Third Wave, Mr. Ganske held various operational, engineering and regulatory management positions over 18 years, including Director of Regulatory Affairs, with Becton Dickinson and Company (BDX).


Brian Fielding

CFO


Mr. Fielding brings over 30 years of strategic, financial, operations and administrative management to CellAegis. Throughout his career Mr. Fielding has worked extensively with Private Equity, Venture and Publicly financed organizations.

Prior to joining CellAegis, Mr. Fielding served as CFO of Therapure BioPharma Inc., creating Canada’s leading provider of biological contract manufacturing services to the Life Science industry as well as a leading drug development company focusing on plasma derived therapeutics, liver cancer, anemia and hepatitis C.

Prior to Therapure BioPharma Inc. Mr. Fielding worked with a broad portfolio of development, service provider and commercial Life Science organizations and has operated as CEO, COO and CFO within these organizations. Mr. Fielding has worked with Medical Device, Diagnostic and Therapeutic technologies throughout his career.

Mr. Fielding is a CA, CPA and has a Bachelor of Commerce from the University of Toronto.


Vera Belaoussoff

VP, Clinical and Corporate Development


Ms. Belaoussoff has over 20 years of experience in research and the healthcare industry. She is currently VP, Corporate Development at CellAegis Devices. Prior to joining CellAegis Devices, Ms. Belaoussoff was responsible for pipeline development at YM BioSciences, a development-stage oncology company, where she was responsible for the acquisition of Australian Cytopia Ltd for the JAK inhibitor CYT387, which subsequently resulted in YM BioSciences’ acquisition by US-based Gilead Sciences in 2013.

Ms. Belaoussoff has also provided consulting services to the biotechnology industry, with a focus on strategic development and out-licensing. Ms. Belaoussoff was a healthcare analyst for eight years in the financial services industry, most recently on the buy-side with Scotia Cassels Investment Management where she covered the North American healthcare industry. Prior to that, she was a healthcare analyst in the brokerage industry and participated in over $80 million of biotech financing. Ms. Belaoussoff has her M.Sc. (Molecular Biology) from York University in Toronto, and an Honour’s B.Sc. (Genetics) from the University of Manitoba.


Michaela Shaw

Quality & Regulatory Affairs Manager


Ms. Shaw brings over 10 years experience within the medical device industry where she has focused on leading innovative, start-up medical device firms through the maze of the quality assurance and regulatory requirements to become successful and viable commercial enterprises.

Ms. Shaw has expertise helping companies certify their Quality Management Systems to ISO 13485 and obtain Health Canada, European (CE Mark), Australian and FDA market approvals. Ms. Shaw understands the unique needs of innovative, technology-driven businesses and focuses on developing quality and regulatory strategies that are flexible enough to allow the creative innovations to thrive, while still focusing on the critical medical device regulatory priorities of safety and efficacy.

Marshal Linder

Corporate Senior VP Zoll Medical


Christopher Colecchi

Managing Director, Broadview Ventures



Shermaine Tilley

Managing Partner, CTI Life Sciences Fund


Donna Parr

President, Crimson Capital



Brian Roberts

Entrepreneur, Asia Pacific


Rocky Ganske

CEO, CellAegis Devices Inc.



Professor Kim Fox, Chair of SAB

Clinical Cardiology, Royal Brompton College, London, UK


Dr. Fox’s expertise is in the understanding, investigation and treatment of angina; in particular the role of heart rate in the pathophysiology of myocardial ischaemia and infarction. He has published over 500 papers in leading scientific journals.

He has played a major role in many important international clinical trials (EUROPA, IONA, BEAUTIFUL, HPS, ASCOT, SEARCH, PERFORM, SIGNIFY, etc) that have changed the treatment of this condition. He is the acknowledged European expert in this field and consequently chaired the Task Force producing the European Angina Guidelines and chaired the committee responsible for the audit for the management of these patients in Europe.

Dr. Fox holds the Diana, Princess of Wales Chair in Cardiovascular Medicine and Science and is a Consultant Cardiologist at the Royal Brompton Hospital. He is a non-Executive Director of the Royal Brompton and Harefield NHS Foundation Trust and serves as a Trustee of the Institute of Cardiovascular Medicine and Science as well as the Magdi Yacoub Institute.

Previously, Dr. Fox was Head of the National Heart and Lung Institute at Imperial College London; President of the European Society of Cardiology 2006-2008; Associate Editor of the British Heart Journal in 1985-1994 and Editor in Chief of the European Heart Journal 1994-2002.

He has previously served as a member of the British Heart Foundation Education Committee (chair), Council and Executive Committee as well as the British Cardiac Society’s Council and Medical Practice Committee (chair).

Professor Jeffrey Borer

Suny Downstate Medical Center, New York USA


Dr. Borer, MD, is Professor of Medicine, Cell Biology, Radiology and Surgery at the State University of New York Downstate Medical Center. He has published almost 500 full-length scientific papers and 7 books, has participated in various roles in numerous clinical trials of therapies, is editor-in-chief of the journal, Cardiology, and has received several awards and other recognitions for his work including, most recently, the Lifetime Achievement Award.

He has been an Advisor to the USFDA for 38 years, chaired the CardioRenal Drugs Advisory Committee for 3 terms and the Circulatory Devices Advisory Panel for one term, was a life sciences Advisor to NASA for 24 years, has served as officer/board member of several national professional societies. His research has been supported by NIH, AHA and, for many years, by several large private foundations.

At Downstate, Dr. Borer has performed clinical service, teaching and research, the latter currently primarily focused on developing prognosticators for regurgitant valve diseases and assessing the effects of heart rate modification on clinical outcomes. Previously at NIH, he developed stress radionuclide cineangiography, an achievement which transformed the practice of cardiology by enabling the first non-invasive assessment of cardiac function with exercise.

Dr. Borer has been involved in many international multi-centre clinical trials (SHIFT, PRECISION-ABPM, EchoCRT, RENEWAL). As a Fellow and Fullbright Scholar, he completed the first clinical demonstration of nitroglycerin's utility in acute myocardial infarction.


Dr. Sarah Clarke

Papworth Hospital, Cambridge, UK


Dr. Clarke is a leader, educator, and is known for her transformative work in health and clinical services. She holds leadership roles locally, regionally, nationally and internationally. She is the first female President of the British Cardiovascular Society (2015 – 2018), a member of Council at the Royal College Physicians (London), the joint National Lead for Cardiology for the government funded GIRFT (Getting It Right First Time) programme aimed at reducing variation, improving quality and cost-effectiveness of services in the NHS.

Dr. Clarke is an Interventional cardiologist and full-time consultant at Royal Papworth Hospital, Cambridge, UK, and Clinical Director of Strategic Development at Papworth Hospital. She is a member of the Board of the European Society of Cardiology (ESC), the European representative at the Association of International Governors at the American College of Cardiology (ACC) and co-chairs the ACC International Centres of Excellence Programme.

Dr. Clarke has been involved in multiple clinical trials, including the CRISP study of remote ischemic conditioning in elective PCI patients showing the benefit on short and long-term outcomes.

Dr. Clarke is past-president of the British Cardiovascular Society (BCS).

Professor Michael Böhm

University of the Saarland, Germany


Dr. Böhm is an interventional cardiologist whose special interests include the pathophysiology and therapy of heart failure. In particular, he is involved in studies on signal transduction in the failing heart and in vascular biology. He has written more than 500 original papers, book chapters and review articles.

Dr. Böhm has been the principal investigator (OPTILINK, SIMPLICITY HTN1, HTN2, EDIFY, SPYRAL) or national coordinator in many other international multicenter studies.

Dr. Böhm is Professor of Internal Medicine and Director of Cardiology at University of the Saarland in Germany. He is Chief editor Clinical Research in Cardiology, Consulting Editor for Basic Research in Cardiology, and on the editorial board and reviewer for most of the recognized scientific journals in the cardiovascular field. He is past-president of the German Society of Cardiology.


Professor Michel Ovize

Claude Bernard University in Lyon, France


Dr. Ovize is a leading expert on the detrimental effects of cardiac ischemia-reperfusion injury and cardioprotective strategies and has been involved in the field of ischemic preconditioning since its inception. He has published extensively in the area of myocardial protection and preservation of mitochondrial function.

Dr. Ovize is a Cardiologist and Professor of Physiology, Head of the Non-Invasive and Stress Testing Cardiology Department at the Louis Pradel Hospital and Head of the INSERM “cardioprotection” team at the Claude Bernard University in Lyon, France. Dr. Ovize has been a reviewer for numerous journals including NEJM, Lancet, Circulation, Circulation Research, European Heart Journal, American Journal of Physiology, and others.

Dr. Ovize is a member of various International Medical Societies, and been involved in multiple clinical trials (CYRYS, CIRCUS, RIPOST-MI, PRECORD, Intra-Co-EpoMI). Currently he is involved as Principal Investigator or European Coordinator in four multi-centre trials funded by the TransAtlantic Leducq Foundation, French National Programmes, and Industry contracts.

Professor JoAnn Lindenfeld

Professor of Medicine, Vanderbilt University, Nashville, USA


Dr. Lindenfeld’s interest is in the area of heart failure, heart transplantation, and mechanical circulatory support. Her recent work has contributed to improved anti-coagulation in recipients of left ventricular assist devices, the development of models to predict the risk of peripartum cardiomyopathy, the discovery that women with heart failure are more likely to have heart failure with preserved ejection fraction, and the development of a model that determines specific phenotypes of heart failure with preserved ejection fraction. She has published extensively in the area of heart failure.

Dr. Lindenfeld has extensive experience in the direction and oversight of large multi-center randomized clinical trials (CAT-HF, GUIDED-HF, FUSION II, COMPANION, 4S and others).

Dr. Lindenfeld is Professor of Medicine and Director of the Heart Failure and Transplant Programs at Vanderbilt University. She developed the heart failure and transplant program at the University of Colorado and is also cofounder of the Center for Women’s Health Research at the University of Colorado.


Professor Teo Forcht Dagi

Queen’s University Belfast, Northern Ireland


Dr. T. (Teo) Forcht Dagi is a neurosurgeon who serves as a distinguished scholar and professor at Queen’s University Belfast. He chaired the international advisory panel for the medical school until 2017 and currently chairs the panel for the school of management.

Dr. Dagi has been involved in multiple societies and councils in the United States: He chaired the Council on Perioperative Care of the American College of Surgeons and the Council on Surgical and Perioperative Safety and served as a Director of the American Association of Neurological Surgeons. He has served as a consultant on medical technologies to the Office of Technology Assessment of the Congress of the United States, and on neurological drugs and devices to the US Food and Drug Administration. He is an editor of Neurosurgery and the Journal of Clinical Ethics. He trained at the Massachusetts General Hospital and served as a neurosurgeon and flight surgeon in the US Army Medical Corps (Reserve).

Dr. Dagi has also been active as a venture capitalist and an entrepreneur in the medical device arena. He has actively managed two investment funds and served as an advisor to industry organizations, investment banks, conventional venture capital organizations and venture philanthropies. He taught in and directed the Harvard-MIT Program in biomedical entrepreneurship and sits on the Board of the Medical Development Group (Boston) and several medical device and biopharma companies. He serves as the CEO of Boston Neurosciences, a non-invasive neuro-monitoring company focused on intracranial pressure and cerebral autoregulation.


Dr. Andrew Redington

CellAegis co-founder


Dr. Redington’s lab published the seminal work (Kharbanda et al 2002) demonstrating that limb remote ischemic conditioning had same effect in the body as invasive ischemic preconditioning, thereby opening the door to the many trials of remote ischemic conditioning in clinical practice to mitigate the effects of ischemia-reperfusion injury.

He also performed the first clinical trial of RIC in humans, which was in pediatric patients with congenital cardiac conditions.

His research interests include remote ischemic conditioning, ventricular function, and integrated physiology of congenital heart disease. Dr. Redington has written more than 300 peer-reviewed publications, more than 30 book chapters, and has co-edited seven textbooks. He currently holds over 15 US and international patents.

Dr. Redington is Executive Co-Director, and Chief of Pediatric Cardiology at The Heart Institute of Cincinnati. Previously he was Chief, Pediatric Cardiology at The Hospital for Sick Children in Toronto, Canada.

Dr. Christopher Caldarone

CellAegis co-founder


Dr. Caldarone’s research interests include the role of apoptosis related mitochondrial dysfunction and remote ischemic preconditioning as mediators of reperfusion injury.

Dr. Christopher Caldarone serves as chief of congenital heart surgery at Baylor College of Medicine/Texas Children’s Hospital. Dr. Caldarone specializes in the management of children and adults with congenital heart disease. His main clinical interests include the treatment of left ventricular outflow tract obstruction, coronary anomalies, and pulmonary vein stenosis.

Dr. Caldarone was previously staff cardiovascular surgeon at the Hospital for Sick Children in Toronto, Canada. He was also Professor of Surgery at the University of Toronto and Surgery-in-Chief for United Health Network in Toronto with oversight of surgery at these hospitals.

Dr. Caldarone received his undergraduate degree from Johns Hopkins University and his medical degree from Columbia University. He completed his cardiothoracic and general surgery residencies at Beth Israel Deaconess Medical Center/Harvard Medical School. He also completed a fellowship in congenital heart surgery at The Hospital for Sick Children.


Get autoRIC®